ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of

0001574232false--12-312025Q26-K2025-06-30Addex Therapeutics Ltd.P5Y1717170001574232ifrs-full:TreasurySharesMemberadxn:KeplerCapitalMarketsSaMember2025-06-300001574232adxn:OtherFinancialAssetsMemberadxn:KeplerCapitalMarketsSaMember2025-06-300001574232ifrs-full:TreasurySharesMemberadxn:KeplerCapitalMarketsSaMember2024-12-310001574232adxn:OtherFinancialAssetsMemberadxn:KeplerCapitalMarketsSaMember2024-12-310001574232ifrs-full:PreferenceSharesMemberifrs-full:TopOfRangeMemberadxn:UnderlyingSharePriceMember2025-06-300001574232ifrs-full:PreferenceSharesMemberifrs-full:BottomOfRangeMemberadxn:UnderlyingSharePriceMember2025-06-300001574232adxn:AntiDilutionProtectionMemberifrs-full:TopOfRangeMemberadxn:SalePriceOfSharesMember2025-06-300001574232adxn:AntiDilutionProtectionMemberifrs-full:BottomOfRangeMemberadxn:SalePriceOfSharesMember2025-06-300001574232adxn:SharesHeldInTreasuryMember2024-12-310001574232adxn:SharesHeldInTreasuryMember2023-12-310001574232adxn:NeurosterixGroupMember2025-04-012025-06-300001574232adxn:NeurosterixGroupMember2025-01-012025-06-300001574232adxn:NeurosterixGroupMember2024-04-032025-06-300001574232ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2025-06-300001574232ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2025-06-300001574232ifrs-full:LandAndBuildingsMember2025-06-300001574232ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2024-12-310001574232ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2024-12-310001574232ifrs-full:LandAndBuildingsMember2024-12-310001574232ifrs-full:LandAndBuildingsMember2023-12-310001574232adxn:IfrsEquipmentMember2023-12-310001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2025-04-012025-06-300001574232adxn:JanssenPharmaceuticalsInc.Memberadxn:DevelopmentMember2025-01-012025-06-300001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2025-01-012025-06-300001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2024-04-012024-06-300001574232adxn:JanssenPharmaceuticalsInc.Memberadxn:DevelopmentMember2024-01-012024-06-300001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2024-01-012024-06-300001574232adxn:IndiviorPlcMemberadxn:RightsGrantedMember2018-01-012018-01-310001574232ifrs-full:IndividuallyInsignificantCounterpartiesMember2025-04-012025-06-300001574232adxn:NeurosterixGroupMember2025-04-012025-06-300001574232ifrs-full:IndividuallyInsignificantCounterpartiesMember2025-01-012025-06-300001574232adxn:NeurosterixGroupMember2025-01-012025-06-300001574232adxn:IndiviorPlcMember2024-04-012024-06-300001574232ifrs-full:IndividuallyInsignificantCounterpartiesMember2024-01-012024-06-300001574232adxn:IndiviorPlcMember2024-01-012024-06-300001574232adxn:NeurosterixUsHoldingsLlcMember2025-06-302025-06-300001574232ifrs-full:GrossCarryingAmountMemberadxn:IfrsEquipmentMember2025-06-300001574232ifrs-full:AccumulatedDepreciationAndAmortisationMemberadxn:IfrsEquipmentMember2025-06-300001574232ifrs-full:GrossCarryingAmountMember2025-06-300001574232ifrs-full:AccumulatedDepreciationAndAmortisationMember2025-06-300001574232adxn:IfrsEquipmentMember2025-06-300001574232ifrs-full:GrossCarryingAmountMemberadxn:IfrsEquipmentMember2024-12-310001574232ifrs-full:AccumulatedDepreciationAndAmortisationMemberadxn:IfrsEquipmentMember2024-12-310001574232adxn:IfrsEquipmentMember2024-12-310001574232adxn:IfrsEquipmentMember2023-12-310001574232ifrs-full:PreferenceSharesMemberadxn:UnderlyingSharePriceMember2025-06-300001574232adxn:WarrantsReceivedOnInvestmentsClassTwoMemberadxn:UnderlyingSharePriceMember2025-06-300001574232adxn:WarrantsReceivedOnInvestmentsClassOneMemberadxn:UnderlyingSharePriceMember2025-06-300001574232adxn:PhantomSharesMemberadxn:UnderlyingSharePriceMember2025-06-300001574232adxn:AntiDilutionProtectionMemberadxn:SalePriceOfSharesMember2025-06-300001574232ifrs-full:DiscontinuedOperationsMemberadxn:EurostarsInnosuisseMemberadxn:Mglu2NamProgramMember2024-01-012024-04-020001574232country:US2025-04-012025-06-300001574232country:FR2025-04-012025-06-300001574232country:CH2025-04-012025-06-300001574232country:US2025-01-012025-06-300001574232country:FR2025-01-012025-06-300001574232country:CH2025-01-012025-06-300001574232country:US2024-04-012024-06-300001574232country:FR2024-04-012024-06-300001574232country:CH2024-04-012024-06-300001574232country:US2024-01-012024-06-300001574232country:FR2024-01-012024-06-300001574232country:CH2024-01-012024-06-300001574232ifrs-full:OrdinarySharesMember2024-12-310001574232adxn:EmployeeShareOptionPlansMember2025-06-300001574232adxn:EmployeeShareOptionPlansMember2024-12-310001574232adxn:DeferredStrikePricePaymentPlanMember2025-06-300001574232adxn:DeferredStrikePricePaymentPlanMember2024-12-310001574232ifrs-full:WarrantsMember2025-06-300001574232country:FR2025-06-300001574232country:CH2025-06-300001574232country:FR2024-12-310001574232country:CH2024-12-310001574232ifrs-full:PresentValueOfDefinedBenefitObligationMember2025-06-300001574232ifrs-full:PlanAssetsMember2025-06-300001574232ifrs-full:PresentValueOfDefinedBenefitObligationMember2024-12-310001574232ifrs-full:PlanAssetsMember2024-12-310001574232adxn:NeurosterixGroupMember2025-06-300001574232adxn:NeurosterixGroupMember2025-03-310001574232adxn:NeurosterixGroupMember2024-12-310001574232adxn:NeurosterixGroupMember2024-06-300001574232adxn:NeurosterixGroupMember2024-04-020001574232ifrs-full:GrossCarryingAmountMemberadxn:ServiceAgreementMember2024-12-310001574232ifrs-full:AccumulatedDepreciationAndAmortisationMemberadxn:ServiceAgreementMember2024-12-310001574232ifrs-full:GrossCarryingAmountMember2024-12-310001574232ifrs-full:AccumulatedDepreciationAndAmortisationMember2024-12-310001574232ifrs-full:PreferenceSharesMemberadxn:UnderlyingSharePriceMember2025-06-302025-06-300001574232adxn:WarrantsReceivedOnInvestmentsClassTwoMemberadxn:UnderlyingSharePriceMember2025-06-302025-06-300001574232adxn:WarrantsReceivedOnInvestmentsClassOneMemberadxn:UnderlyingSharePriceMember2025-06-302025-06-300001574232adxn:PhantomSharesMemberadxn:UnderlyingSharePriceMember2025-06-302025-06-300001574232adxn:AntiDilutionProtectionMemberadxn:SalePriceOfSharesMember2025-06-302025-06-300001574232ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:WarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001574232ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberadxn:PhantomSharesMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001574232ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberadxn:AntiDilutionProtectionMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001574232ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:PreferenceSharesMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001574232ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2025-06-300001574232ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:WarrantsMember2025-06-300001574232ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberadxn:PhantomSharesMember2025-06-300001574232ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberadxn:AntiDilutionProtectionMember2025-06-300001574232ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:PreferenceSharesMember2025-06-300001574232ifrs-full:AccumulatedImpairmentMemberadxn:ContractAssetsAndTradeAndOtherReceivablesMember2025-06-300001574232ifrs-full:PreferenceSharesMember2025-06-300001574232ifrs-full:AtFairValueMember2025-06-300001574232adxn:WarrantsReceivedOnInvestmentsClassTwoMember2025-06-300001574232adxn:WarrantsReceivedOnInvestmentsClassOneMember2025-06-300001574232adxn:PhantomSharesMember2025-06-300001574232adxn:AntiDilutionProtectionMember2025-06-300001574232ifrs-full:AccumulatedImpairmentMemberadxn:ContractAssetsAndTradeAndOtherReceivablesMember2024-12-310001574232ifrs-full:TreasurySharesMember2025-06-300001574232ifrs-full:SharePremiumMember2025-06-300001574232ifrs-full:RetainedEarningsMember2025-06-300001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-06-300001574232ifrs-full:OtherEquityInterestMember2025-06-300001574232ifrs-full:IssuedCapitalMember2025-06-300001574232adxn:OtherReserveMember2025-06-300001574232ifrs-full:TreasurySharesMember2025-03-310001574232ifrs-full:SharePremiumMember2025-03-310001574232ifrs-full:RetainedEarningsMember2025-03-310001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-03-310001574232ifrs-full:OtherEquityInterestMember2025-03-310001574232ifrs-full:IssuedCapitalMember2025-03-310001574232adxn:OtherReserveMember2025-03-3100015742322025-03-310001574232ifrs-full:TreasurySharesMember2024-12-310001574232ifrs-full:SharePremiumMember2024-12-310001574232ifrs-full:RetainedEarningsMember2024-12-310001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001574232ifrs-full:OtherEquityInterestMember2024-12-310001574232ifrs-full:IssuedCapitalMember2024-12-310001574232adxn:OtherReserveMember2024-12-310001574232ifrs-full:TreasurySharesMember2024-06-300001574232ifrs-full:SharePremiumMember2024-06-300001574232ifrs-full:RetainedEarningsMember2024-06-300001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-06-300001574232ifrs-full:OtherEquityInterestMember2024-06-300001574232ifrs-full:IssuedCapitalMember2024-06-300001574232adxn:OtherReserveMember2024-06-300001574232ifrs-full:TreasurySharesMember2024-03-310001574232ifrs-full:SharePremiumMember2024-03-310001574232ifrs-full:RetainedEarningsMember2024-03-310001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-03-310001574232ifrs-full:OtherEquityInterestMember2024-03-310001574232ifrs-full:IssuedCapitalMember2024-03-310001574232adxn:OtherReserveMember2024-03-3100015742322024-03-310001574232ifrs-full:TreasurySharesMember2023-12-310001574232ifrs-full:SharePremiumMember2023-12-310001574232ifrs-full:RetainedEarningsMember2023-12-310001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001574232ifrs-full:OtherEquityInterestMember2023-12-310001574232ifrs-full:IssuedCapitalMember2023-12-310001574232adxn:OtherReserveMember2023-12-310001574232ifrs-full:LandAndBuildingsMember2025-01-012025-06-300001574232adxn:IfrsEquipmentMember2024-01-012024-12-310001574232adxn:IfrsEquipmentMember2025-01-012025-06-300001574232ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMemberadxn:EurostarsInnosuisseMemberadxn:Mglu2NamProgramMember2024-04-020001574232ifrs-full:RetainedEarningsMember2025-04-012025-06-300001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-04-012025-06-300001574232ifrs-full:RetainedEarningsMember2025-01-012025-06-300001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-06-300001574232ifrs-full:RetainedEarningsMember2025-01-012025-03-310001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-03-310001574232adxn:OtherReserveMember2025-01-012025-03-310001574232ifrs-full:RetainedEarningsMember2024-04-012024-06-300001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-04-012024-06-300001574232adxn:OtherReserveMember2024-04-012024-06-300001574232ifrs-full:RetainedEarningsMember2024-01-012024-06-300001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-06-300001574232adxn:OtherReserveMember2024-01-012024-06-300001574232ifrs-full:RetainedEarningsMember2024-01-012024-03-310001574232ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-03-310001574232adxn:OtherReserveMember2024-01-012024-03-3100015742322023-12-310001574232adxn:NeurosterixPharmaSarlMember2025-06-300001574232ifrs-full:KeyManagementPersonnelOfEntityOrParentMemberadxn:AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember2024-06-300001574232adxn:IfrsEquipmentMember2024-01-012024-12-310001574232adxn:ServiceAgreementMember2024-01-012024-12-310001574232adxn:IndiviorPlcMemberadxn:AchievementOfPreSpecifiedMilestonesMember2018-01-020001574232adxn:JanssenPharmaceuticalsInc.Memberadxn:DevelopmentMemberifrs-full:TopOfRangeMember2004-12-310001574232ifrs-full:MajorOrdinaryShareTransactionsMember2025-07-012025-09-290001574232adxn:TreasurySharesSoldUnderSaleAgencyAgreementMember2025-01-012025-06-300001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2023-07-012024-06-300001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2021-05-012022-07-310001574232ifrs-full:PreferenceSharesMemberadxn:StaliclaSaMemberadxn:UnderlyingSharePriceMember2025-06-012025-06-300001574232adxn:EurostarsInnosuisseMemberadxn:Mglu2NamProgramMember2023-12-012023-12-310001574232adxn:StaliclaSaMember2025-06-012025-06-300001574232adxn:AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMemberadxn:NeurosterixUsHoldingsLlcMember2024-04-022024-04-020001574232adxn:NeurosterixUsHoldingsLlcMember2024-04-022024-04-020001574232currency:USD2025-01-012025-06-300001574232currency:GBP2025-01-012025-06-300001574232currency:EUR2025-01-012025-06-300001574232currency:CHF2025-01-012025-06-300001574232currency:USD2024-01-012024-12-310001574232currency:GBP2024-01-012024-12-310001574232currency:EUR2024-01-012024-12-310001574232currency:CHF2024-01-012024-12-310001574232adxn:P1Or1Member2025-06-300001574232ifrs-full:OrdinarySharesMember2023-12-3100015742322024-02-202024-02-200001574232adxn:SharesHeldInTreasuryMember2025-06-300001574232adxn:SharesHeldInTreasuryMember2024-06-3000015742322024-06-300001574232ifrs-full:OrdinarySharesMember2025-06-300001574232ifrs-full:OrdinarySharesMember2024-06-300001574232adxn:StaliclaSaMember2025-06-012025-06-300001574232adxn:IndiviorPlcMemberadxn:IndiviorPlcMemberadxn:IfrsResearchMember2018-01-022018-01-020001574232adxn:IndiviorPlcMember2018-01-022018-01-020001574232ifrs-full:TreasurySharesMember2025-04-012025-06-300001574232ifrs-full:TreasurySharesMember2025-01-012025-06-300001574232ifrs-full:TreasurySharesMember2025-01-012025-03-310001574232ifrs-full:SharePremiumMember2025-01-012025-03-3100015742322025-01-012025-03-310001574232ifrs-full:TreasurySharesMember2024-04-012024-06-300001574232ifrs-full:TreasurySharesMember2024-01-012024-06-300001574232ifrs-full:TreasurySharesMember2024-01-012024-03-3100015742322025-06-3000015742322024-12-310001574232ifrs-full:DiscontinuedOperationsMember2024-04-012024-06-300001574232ifrs-full:DiscontinuedOperationsMember2024-01-012024-06-300001574232adxn:NeurosterixGroupMember2024-04-012024-06-300001574232adxn:NeurosterixGroupMember2024-01-012024-06-300001574232ifrs-full:LandAndBuildingsMember2024-01-012024-12-3100015742322024-01-012024-12-310001574232adxn:OtherReserveMember2025-04-012025-06-300001574232adxn:OtherReserveMember2025-01-012025-06-300001574232adxn:NeurosterixGroupMember2025-01-012025-06-300001574232adxn:AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember2024-04-022024-04-020001574232adxn:NeurosterixGroupMember2025-04-012025-06-300001574232adxn:NeurosterixGroupMember2025-01-012025-06-300001574232adxn:WarrantsReceivedOnInvestmentsClassTwoMemberadxn:StaliclaSaMember2025-06-012025-06-300001574232adxn:WarrantsReceivedOnInvestmentsClassOneMemberadxn:StaliclaSaMember2025-06-012025-06-300001574232adxn:TreasurySharesSoldOtherThanUnderSaleAgencyAgreementMember2025-01-012025-06-300001574232ifrs-full:OrdinarySharesMember2023-12-122023-12-310001574232adxn:AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember2025-04-012025-06-300001574232ifrs-full:SharePremiumMember2025-04-012025-06-3000015742322025-04-012025-06-300001574232ifrs-full:SharePremiumMember2025-01-012025-06-300001574232ifrs-full:SharePremiumMember2024-04-012024-06-3000015742322024-04-012024-06-300001574232ifrs-full:SharePremiumMember2024-01-012024-06-300001574232ifrs-full:SharePremiumMember2024-01-012024-03-3100015742322024-01-012024-03-310001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2018-01-022018-01-020001574232adxn:EurostarsInnosuisseMemberadxn:Mglu2NamProgramMember2023-09-012023-09-300001574232adxn:AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember2024-04-012024-06-300001574232adxn:AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember2024-01-012025-06-300001574232adxn:NeurosterixPharmaSarlMember2024-04-022024-04-020001574232adxn:StaliclaSaMember2025-06-300001574232adxn:AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember2025-01-012025-06-300001574232adxn:AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember2024-01-012024-06-300001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2023-07-012023-07-010001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2022-11-012022-11-010001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2022-08-012022-08-310001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2021-05-012021-05-010001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2020-10-302020-10-300001574232adxn:IndiviorPlcMemberadxn:IfrsResearchMember2019-01-012019-12-310001574232adxn:SharesHeldInTreasuryMember2025-01-012025-06-3000015742322025-01-012025-06-300001574232adxn:SharesHeldInTreasuryMember2024-01-012024-06-3000015742322024-01-012024-06-30adxn:EquityInstrumentsadxn:Optionsxbrli:sharesiso4217:USDiso4217:CHFiso4217:CHFxbrli:sharesadxn:categoryadxn:itemadxn:segmentxbrli:pureiso4217:EUR

ADDEX THERAPEUTICS LTD

INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Addex Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Balance Sheets

as of June 30, 2025, and December 31, 2024

The accompanying notes form an integral part of these consolidated financial statements.

Addex Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements of Profit or Loss

for the three-month and six-month periods ended June 30, 2025 and 2024

The accompanying notes form an integral part of these consolidated financial statements.

Addex Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements of Comprehensive Income or Loss

for the three-month and six-month periods ended June 30, 2025 and 2024

The accompanying notes form an integral part of these consolidated financial statements.

Addex Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements of Changes in Equity

for the six-month periods ended June 30, 2025 and 2024

The accompanying notes form an integral part of these consolidated financial statements.

Addex Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements of Changes in Equity

for the three-month periods ended June 30, 2024

The accompanying notes form an integral part of these consolidated financial statements.

Addex Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements of Changes in Equity

for the three-month periods ended June 30, 2025

The accompanying notes form an integral part of these consolidated financial statements.

Addex Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements of Cash Flows

for the six-month periods ended June 30, 2025 and 2024

The accompanying notes form an integral part of these consolidated financial statements.

Addex Therapeutics Unaudited Interim Condensed consolidated Financial statements Notes

Unaudited Notes to the Interim Condensed Consolidated Financial Statements

for the six-month period ended June 30, 2025

(Amounts in Swiss francs)

1. General information

Addex Therapeutics Ltd (the "Company") and its subsidiaries (together, the "Group") are a clinical stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders.

The Company is a Swiss stockholding corporation domiciled c/o Addex Pharma SA, Chemin des Aulx 12, CH 1228 Plan-les-Ouates, Geneva, Switzerland and the parent company of Addex Pharma SA, Addex Pharmaceuticals France SAS and Addex Pharmaceuticals Inc. Addex Therapeutics also owns a 20% equity interest in Neurosterix US Holdings LLC, USA. Neurosterix US Holdings LLC fully owns directly Neurosterix Swiss Holdings AG, Switzerland and indirectly Neurosterix Pharma S rl whose principal place of business is Chemin des Mines 9, CH 1202 Geneva, Switzerland.

The Groups principal place of business is Chemin des Mines 9, CH 1202 Geneva, Switzerland. Its registered shares are traded at the SIX Swiss Exchange, under the ticker symbol ADXN and its American Depositary Shares (ADSs) on the Nasdaq Stock Market under the symbol ADXN. ADSs represents shares that continue to be admitted to trading on SIX Swiss Exchange.

These interim condensed consolidated financial statements have been approved for issuance by the Board of Directors on September 29, 2025.

2. Basis of preparation

These interim condensed consolidated financial statements for the six-month period ended June 30, 2025, have been prepared under the historic cost convention and in accordance with IAS 34 "Interim Financial Reporting" and are presented in a format consistent with the consolidated financial statements under IAS 1 "Presentation of Financial Statements". However, they do not include all of the notes that would be required in a complete set of financial statements. Thus, this interim financial report should be read in conjunction with the consolidated financial statements for the year ended December 31, 2024.

Interim financial results are not necessarily indicative of results anticipated for the full year. The preparation of these unaudited interim condensed consolidated financial statements made in accordance with IAS 34 requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management's best knowledge of current events and actions, actual results ultimately may differ from those estimates. The areas involving a higher degree of judgment which are significant to the interim condensed consolidated financial statements are disclosed in note 4 to the consolidated financial statements for the year ended December 31, 2024.

A number of new or amended standards and interpretations became applicable for financial reporting periods beginning on or after January 1, 2025. Of the latter, the Group noted the amendment of IAS 21: The Effects of Changes in Foreign Exchange rates relating to the exchange rate of currencies that are not exchangeable. The Group concluded that this amendment was not relevant as the Group only uses major currencies. The Group is also assessing other new and revised standards which are not mandatory until after 2025 and noted that IFRS 18 - Presentation and Disclosure in Financial Statements will replace IAS 1 - Presentation of Financial Statements - from January 1, 2027 and may impact the presentation and structure of the Group's primary financial statements and related disclosures.

Due to rounding, numbers presented throughout these interim condensed consolidated financial statements may not add up precisely to the totals provided. All ratios and variances are calculated using the underlying amounts rather than the presented rounded amounts. Where necessary, comparative figures have been revised to conform with the current year 2025.

Addex Therapeutics Unaudited Interim Condensed consolidated Financial statements Notes

3. Material accounting estimates and judgments

The Group makes estimates and assumptions concerning the future. These estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities or may have had a significant impact on the reported results are disclosed below:

The Group's accounts are prepared on a going concern basis. To date, the Group has financed its cash requirements primarily from share issuances, licensing certain of its research and development stage products and selling its allosteric modulator drug discovery technology platform with a portfolio of preclinical programs. The Group is a development-stage enterprise and is exposed to all the risks inherent in establishing a business. The Group expects that its existing cash and cash equivalents, at the issuance date of these unaudited interim condensed consolidated financial statements will be sufficient to fund its operations and meet all of its obligations as they fall due, through mid-June 2026. These factors individually and collectively indicate that a material uncertainty exists that raises substantial doubt about the Group's ability to continue as a going concern for one year from the date of issuance of these unaudited interim condensed consolidated financial statements. The future viability of the Group is dependent on its ability to raise additional capital through public or private financings or collaboration agreements to finance its future operations, which may be delayed due to reasons outside of the Group's control including health pandemics and geopolitical risks. The sale of additional equity may dilute existing shareholders. The inability to obtain funding, as and when needed, would have a negative impact on the Group's financial condition and ability to pursue its business strategies. If the Group is unable to obtain the required funding to run its operations and to develop and commercialize its product candidates, the Group could be forced to delay, reduce or stop some or all of its research and development programs to ensure it remains solvent. Management continues to explore options to obtain additional funding, including through collaborations with third parties related to the future potential development and/or commercialization of its product candidates. However, there is no assurance that the Group will be successful in raising funds, closing collaboration agreements, obtaining sufficient funding on terms acceptable to the Group, or if at all, which could have a material adverse effect on the Group's business, results of operations and financial condition.

The Business of the Group could be adversely affected by health pandemics and geopolitical risks

The business of the Group could be adversely affected by health epidemics and geopolitical risks in regions where the Group or partners have concentrations of clinical trial sites or other business operations and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom the Group or partners rely. Health pandemics may pose the risk that the Group, employees, contractors, collaborators, and partners may be prevented from conducting certain pre-clinical tests, clinical trials or other business activities for an indefinite period of time, including due to travel restrictions, quarantines, "stay-at-home" and "shelter-in-place" orders or shutdowns that have been or may in the future be requested or mandated by governmental authorities. For example, the COVID-19 pandemic has impacted the business of the Group and clinical trials led by the Group or partners, including as a result of delays or difficulties in clinical site initiation, difficulties in recruiting and retaining clinical site investigators and clinical site staff and interruption of the clinical supply chain or key clinical trial activities, such as clinical trial site monitoring, and supply chain interruptions caused by restrictions for the supply of materials for drug candidates or other materials necessary to manufacture product to conduct clinical and preclinical tests. Geopolitical risks such as Russia-Ukraine war or Middle East conflict may create global security concerns including the possibility of an expanded regional or global conflict and potential ramifications such as disruption of the supply chain including research and development activities being conducted by the Group and its strategic partners. Delays in research and development activities of the Group and its partners could increase associated costs and, depending upon the duration of any delays, require the Group and its partners to find alternative suppliers at additional expense. In addition, Russia-Ukraine war has had significant ramifications on global financial markets, which may adversely impact the ability of the Group to raise capital on favorable terms or at all.

Addex Therapeutics Unaudited Interim Condensed consolidated Financial statements Notes

Discontinued operations, assets and liabilities held for sale related to the Neurosterix Transaction

On April 2, 2024, the Group sold a part of its business constituting its allosteric modulator drug discovery technology platform and a portfolio of preclinical programs (note 21). As a consequence, the Group recognized discontinued operations in the statements of profit or loss under "net profit or loss from discontinued operations" for the six month-period ended June 30, 2024, in accordance with IFRS 5. The Group identified as well, cash flows from discontinued operations for the six-month period ended June 30, 2024 (note 21). The identification of discontinued operations may require some degree of judgement.

Fair value measurement of financial instruments

The Group measures its financial instruments at fair value at each reporting date. Fair value is the price that would be received to sell its financial asset in an orderly transaction between market participants at the measurement date, in the principal or most advantageous market, under current market conditions. Fair value measurements are categorized into three levels based on the degree to which inputs to the valuation techniques are observable:

The Group uses appropriate valuation techniques in the circumstances and maximizes the use of relevant observable inputs. The transfers between levels are assessed at the end of each reporting period.

Investments accounted for using the equity method

The Group received an equity interest of 20% in Neurosterix US Holdings LLC as part of the Neurosterix Transaction. The initial recognition of the investment has been accounted at a fair value based on a financial valuation of Neurosterix Group. This carrying amount has been decreased to recognize the share of loss of Neurosterix Group and tested for impairment whenever events, factors or changes in circumstances indicate that it may not be recoverable.

Financial assets at fair value through Other Comprehensive Income (OCI)

The financial assets at fair value through OCI relate to strategic investments made by the Group into early stage R&D companies. The Group made the irrevocable election to classify these strategic investments, that are not held for trading, at fair value through OCI. The valuation at fair value is based on prices paid by investors during recent fundings (note 23). At each closing, the investments are tested by the Group in order to reflect any change in value due to events, factors or changes in circumstances.

Derivative financial instruments

Derivative financial instruments relate to Phantom shares and Warrants received as part of the purchase of strategic investment. Derivative financial instruments are accounted at fair value through the statements of profit or loss in accordance with IFRS 9, because they are considered as held for trading. The fair value is measured using the black Scholes and binomial valuation models (note 24). A number of assumptions related to the volatility of the underlying shares and to the risk - free rate are made in this model. Should the assumptions and estimates underlying the fair value of these instruments vary significantly from management's estimates, then the fair value of the derivative financial instruments would be materially different from the amounts recognized. At each closing, the investments are tested by the Group in order to reflect any change in value due to events, factors or changes in circumstances.

Addex Therapeutics Unaudited Interim Condensed consolidated Financial statements Notes

Revenue is primarily from fees related to licenses, milestones and research services. Given the complexity of the relevant agreements, judgements are required to identify distinct performance obligations, allocate the transaction price to these performance obligations and determine when the performance obligations are met. In particular, the Group's judgement over the estimated stand-alone selling price which is used to allocate the transaction price to the performance obligations is disclosed in note 16.

Grants are recorded at their fair value when there is reasonable assurance that they will be received and recognized as income when the Group has satisfied the underlying grant conditions. In certain circumstances, grant income may be recognized before explicit grantor acknowledgement that the conditions have been met.

Accrued research and development costs

The Group records accrued expenses for estimated costs of research and development activities conducted by third party service providers. The Group records accrued expenses for estimated costs of research and development activities based upon the estimated amount of services provided, but not yet invoiced, and these costs are included in accrued expenses on the balance sheets and within research and development expenses in the statements of profit or loss. These costs are a significant component of research and development expenses. Accrued expenses for these costs are recorded based on the estimated amount of work completed in accordance with agreements established with these third parties. Due to the nature of estimates, the Group may be required to make changes to the estimates after a reporting period as it becomes aware of additional information about the status or conduct of its research activities.

Share-based compensation

The Group recognizes an expense for share-based compensation based on the valuation of equity incentive units using the Black-Scholes valuation model. A number of assumptions related to the volatility of the underlying shares and to the risk-free rate are made in this model. Should the assumptions and estimates underlying the fair value of these instruments vary significantly from management's estimates, then the share-based compensation expense would be materially different from the amounts recognized.

The group records in equity the pre-funded warrants sold to investors and the warrants granted to investors at a fair value calculated using Black-Scholes model. A number of assumptions related to the volatility of the underlying shares and to the risk - free rate are made in this model. Should the assumptions and estimates underlying the fair value of these instruments vary significantly from management's estimates, then the fair value of the equity instruments would be materially different from the amounts recorded in equity at the grant date.

The present value of the pension obligations is calculated by an independent actuary and depends on a number of assumptions that are determined on an actuarial basis such as discount rates, future salary and pension increases, and mortality rates. Any changes in these assumptions will impact the carrying amount of pension obligations. The Group determines the appropriate discount rate at the end of each period. This is the interest rate that should be used to determine the present value of estimated future cash outflows expected to be required to settle the pension obligations. In determining the appropriate discount rate, the Group considers the interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating the terms of the related pension liability. Other key assumptions for pension obligations are based in part on current market conditions. Additional information is disclosed in note 15.

4. Interim measurement note

Seasonality of the business: The business is not subject to any seasonality, but expenses and corresponding revenue are largely determined by the phase of the respective projects, particularly with regard to external research and development expenditures.

Addex Therapeutics Unaudited Interim Condensed consolidated Financial statements Notes

Costs: Costs that incur unevenly during the financial year are anticipated or deferred in the interim report only if it would also be appropriate to anticipate or defer such costs at the end of the financial year.

5. Segment reporting

Management has identified one single operating segment, related to the discovery, development and commercialization of small-molecule pharmaceutical products.

Information about products, services and major customers

External income of the Group is derived from the business of discovery, development and commercialization of pharmaceutical products. Income primarily relates to research services provided to a pharmaceutical company and the fair value of services received from Neurosterix Group at zero cost (notes 10 and 21).

Information about geographical areas

External income is exclusively recorded in the Swiss operating company.

Analysis of revenue from contract with customer and other income by nature is detailed as follows:

Analysis of revenue from contract with customer and other income by major counterparties is detailed as follows:

For more detail, refer to note 16 "Revenue from contract with customer" and note 17 "Other income".

The geographical allocation of long-lived assets is detailed as follows:

Addex Therapeutics Unaudited Interim Condensed consolidated Financial statements Notes

The geographical analysis of operating costs is as follows: